PF-Atlas › Clinical Trials › NCT00581997

QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis

QAX576 · Phase 2

Registry ID
NCT00581997
Phase
Phase 2
Status
Terminated
Drug / intervention
QAX576
Sponsor
Novartis Pharmaceuticals
Start
2007-12
Enrollment
8

About this trial

This study will evaluate the safety, tolerability, and mechanism of action of multiple doses of QAX576 in patients with pulmonary fibrosis secondary to systemic sclerosis

View NCT00581997 on ClinicalTrials.gov →

Explore related

All QAX576 trialsAll IPF trials

Related trials

QAX576 — NCT00532233QAX576 — NCT01266135
Medical disclaimer. This page summarizes public trial data for NCT00581997 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.